Latest News and Press Releases

--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction of bleeding with abelacimab compared to rivaroxaban (Xarelto) was even greater in patients ≥75...

Secondary endpoints also showed a highly significant 67% reduction in major bleeding and an 89% reduction in gastrointestinal (GI) bleeding The company’s AZALEA-TIMI 71 study is the longest...

Data presented at the American Heart Association Scientific Sessions show a 67% reduction in bleeding for patients on antiplatelet therapy taking abelacimab as compared to rivaroxaban AZALEA-TIMI 71...

CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the...

CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the...

75% of patients in the rivaroxaban arm voluntarily switched from the once-daily oral anticoagulant to once-monthly abelacimab Landmark AZALEA-TIMI 71 Study previously stopped early due to an...

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by...

Patient-Centric Survey Conducted in Collaborationwith StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology,...

不足 26% 的中国房颤患者接受抗凝剂治疗，而在日本近三分之一的患者未得到充分治疗 在中国约 63% 的癌症患者在确诊后的前 6 个月内出现静脉血栓栓塞症 Abelacimab 已在 23 个国家/地区进行研究 包括北美、欧洲和亚太地区的其他地方 马萨诸塞州剑桥市, June 09, 2023 (GLOBE NEWSWIRE) -- Anthos Therapeutics...

Weniger als 26 % der chinesischen Patienten mit Vorhofflimmern bekommen einen Gerinnungshemmer verschrieben, während in Japan fast ein Drittel der Patienten unterbehandelt wird Ungefähr 63 % der...